

ANNOUNCEMENT

CHEMOPREVENTION OF BREAST CANCER: SURROGATE ENDPOINTS AND CHEMOPREVENTIVE AGENTS IN SHORT-TERM CLINICAL TRIALS

Granlibakken at Lake Tahoe, California, U.S.A., 6–10 October 1993

Sponsored by The National Cancer Institute

Organizers:

Charles W. Boone and Gary J. Kelloff

The workshop will address: (1) the accurate histopathological characterization of breast lesions; (2) characterization of those intermediate biomarkers in breast tissue which may qualify as surrogate endpoints; (3) major mechanisms of chemopreventive drug action; (4) candidate chemopreventive drugs; (5) ongoing breast cancer chemoprevention trials; and (6) strategies for the design of Phase II clinical trials using surrogate endpoints.

For further information:

Fox Meeting Services
604 South Saltair Avenue
Los Angeles
CA 90049, U.S.A.
Tel. (310) 476-1147
FAX (310) 476-7741